Adjuvant treatment with non‐steroidal anti‐inflammatory drugs (NSAIDs) such as aspirin, celecoxib, and diclofenac also facilitates glioma control by suppressing COX‐2, NF‐κB, and STAT3 activation [59, 60] also points to inflammation as an important target in the development of novel, multi‐modal therapeutic approaches to glioma. Here, STAT3 is linked to central nervous system cancer.